Research ExplorerPublicationsRituximab: is replacement of cyclophosphamide and calcineuri...

Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?

Standard

Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? / Dötsch, Jörg; Müller-Wiefel, Dirk E.; Kemper, Markus J.

In: PEDIATR NEPHROL, Vol. 23, No. 1, 1, 2008, p. 3-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dötsch, J, Müller-Wiefel, DE & Kemper, MJ 2008, 'Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?', PEDIATR NEPHROL, vol. 23, no. 1, 1, pp. 3-7. <http://www.ncbi.nlm.nih.gov/pubmed/17899207?dopt=Citation>

APA

Dötsch, J., Müller-Wiefel, D. E., & Kemper, M. J. (2008). Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? PEDIATR NEPHROL, 23(1), 3-7. [1]. http://www.ncbi.nlm.nih.gov/pubmed/17899207?dopt=Citation

Vancouver

Dötsch J, Müller-Wiefel DE, Kemper MJ. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? PEDIATR NEPHROL. 2008;23(1):3-7. 1.

Bibtex

@article{1fe8beadbaeb4dbfab549a385ea4c794,
title = "Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?",
abstract = "The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation. All patients showed remission from steroid dependency for at least 9 months concurring with the reappearance of B lymphocytes that had been eliminated by rituximab. The doses used so far vary between 375 mg/m(2) per dose at weekly intervals for 6 weeks and a single dose of 375 mg/m(2). Until now, with the limited information available, no substantial adverse effects have been reported. However, a recommendation to use rituximab instead of any other established treatment, such as cyclophosphamide, in SDNS cannot be given before clinical studies have been conducted, especially as publication bias cannot be excluded.",
author = "J{\"o}rg D{\"o}tsch and M{\"u}ller-Wiefel, {Dirk E.} and Kemper, {Markus J.}",
year = "2008",
language = "Deutsch",
volume = "23",
pages = "3--7",
journal = "PEDIATR NEPHROL",
issn = "0931-041X",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?

AU - Dötsch, Jörg

AU - Müller-Wiefel, Dirk E.

AU - Kemper, Markus J.

PY - 2008

Y1 - 2008

N2 - The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation. All patients showed remission from steroid dependency for at least 9 months concurring with the reappearance of B lymphocytes that had been eliminated by rituximab. The doses used so far vary between 375 mg/m(2) per dose at weekly intervals for 6 weeks and a single dose of 375 mg/m(2). Until now, with the limited information available, no substantial adverse effects have been reported. However, a recommendation to use rituximab instead of any other established treatment, such as cyclophosphamide, in SDNS cannot be given before clinical studies have been conducted, especially as publication bias cannot be excluded.

AB - The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation. All patients showed remission from steroid dependency for at least 9 months concurring with the reappearance of B lymphocytes that had been eliminated by rituximab. The doses used so far vary between 375 mg/m(2) per dose at weekly intervals for 6 weeks and a single dose of 375 mg/m(2). Until now, with the limited information available, no substantial adverse effects have been reported. However, a recommendation to use rituximab instead of any other established treatment, such as cyclophosphamide, in SDNS cannot be given before clinical studies have been conducted, especially as publication bias cannot be excluded.

M3 - SCORING: Zeitschriftenaufsatz

VL - 23

SP - 3

EP - 7

JO - PEDIATR NEPHROL

JF - PEDIATR NEPHROL

SN - 0931-041X

IS - 1

M1 - 1

ER -